Parkinson Disease
Conditions
Keywords
Parkinson, Allopregnanolone, Regenerative therapeutic
Brief summary
The goal of this open-label, pilot clinical trial is to test allopregnanolone as a regenerative treatment in patients with Parkinson's disease (PD). The main questions this study aims to answer are: 1. Is a large-scale clinical trial testing how well it works in patients with PD feasible? 2. Is allopregnanolone safe and well-tolerated in patients with PD. 3. Can we see any signals of changes in imaging and clinical scales? Participants will receive a weekly infusion in their vein of allopregnanolone for a total of 12 weeks. There is no placebo so everyone receives allopregnanolone and "Open-label" means the study is not blinded so both the participant and investigators know the assigned treatment.
Detailed description
This is an open-label, pilot clinical trial of allopregnanolone (Allo) as a regenerative treatment for Parkinson's disease. A total of 10 study participants will receive weekly infusions of Allo for 12 weeks. Participants will be male and female, age 40-80 years with a history of idiopathic, sporadic PD who have a Hoehn & Yahr stage 1-4. Allo is a potent neuroregenerative agent that promotes proliferation of human neural stem cells and has the potential to function as a regenerative therapeutic to restore motor function in persons with PD. Results from several preclinical studies in rodent models of PD confirm improved motor function after Allo treatment. Primary Objective: To assess the feasibility of a large-scale trial to determine the efficacy of weekly infusions of Allo in in patients with Idiopathic sporadic PD. Secondary Objectives: To evaluate the safety and tolerability of weekly infusions of Allo in participants with idiopathic sporadic PD, and assess single-dose pharmacokinetics of allopregnanolone. Tertiary / Exploratory Objectives: To assess efficacy signals of weekly infusions of Allo in participants with idiopathic sporadic PD. * Determine target engagement of Allo using dopamine transporter (DaT) imaging and magnetic resonance imaging (MRI). * Evaluate effect of Allo on motor function tests. * Evaluate the effect of Allo on cognitive function tests and clinical ratings. * Compare response to Allo administration between APOE4 carriers and non-carriers.
Interventions
DRUGAllopregnanolone
Allopregnanolone is a neurosteroid ( 3α,5α-tetrahydroprogesterone, 3α-hydroxy-5α-pregnan-20-one) and by-product of the metabolism of the hormone progesterone.
Sponsors
Roberta Brinton
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* History of Idiopathic sporadic Parkinson disease * Hoehn \& Yahr stage 1-4 * Have been on stable doses of all anti-Parkinson's medications for 30 days prior to screening * Provision of signed and dated informed consent form
Exclusion criteria
* Evidence of Parkinsonian syndrome. * Any conditions that would contraindicate MRI studies. * Undergone deep brain stimulation (DBS) surgery as treatment for PD. * Iodine allergy, known serious hypersensitivity to ioflupane I-123, or other inability to undergo DaTscan. * Clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness. * History within the last 5 years of a primary or recurrent malignant disease, with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or prostate cancer in situ with a post-treatment prostatic-specific antigen within normal range. * Serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than PD), psychiatric, immunologic, or hematologic disease, and any other conditions that, in the investigator's opinion, could interfere with the safety and efficacy analyses in this study. * History of chronic alcohol or substance abuse/dependence within the past 3 years. * Current use of benzodiazepines, anticonvulsants, antipsychotics, or other drugs that might interact with the gamma-aminobutyric acid-A (GABA-A) receptor complex; use of calcium-channel blockers (e.g., amlodipine); use of dietary supplements containing Pregnenolone. * Treatment with another investigational drug within 3 months of screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Study completion | Week 13 | Proportion of participant progression to study completion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | Weekly from Baseline to Week 16 | Proportion of participants with adverse events to assess safety. |
| Infusion Reactions | Weekly from Week 1 to Week 16 | Proportion of participants with infusion reactions to assess tolerability. |
| Pharmacokinetics: Peak Plasma Concentration (Cmax) | Week 1 | The highest concentration in plasma of allopregnanolone after an IV dose. |
| Pharmacokinetics: Time of peak concentration (tmax) | Week 1 | Time required to achieve peak plasma levels |
| Pharmacokinetics: Half-life (t1/2) | Week 1 | The time required for plasma concentration of Allopregnanolone to decrease by 50%. |
| Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) | Week 1 | The concentration of phytoSERMs in blood plasma as a function of time. Gives insight into the extent of exposure to phytoSERM and its clearance rate from the body. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORScott Sherman, MD
University of Arizona
STUDY_CHAIRRoberta D Brinton, PhD
University of Arizona
STUDY_DIRECTORGerson D Hernandez, MD, MPH
University of Arizona
Outcome results
None listed